

The role of phospholipases in inflammation, gene expression, and apoptosis

Uju Dorothy Iliemene Ejike^a, Mubarak Labaran Liman^b,
Paul T. Olonishuwa^a, and Moses Bali^b

^aDepartment of Biochemistry, Faculty of Science & Technology, Bingham University, Karu, Nigeria

^bDepartment of Science Laboratory Technology, Nuhu Bamalli Polytechnic, Zaria, Nigeria

1 Introduction

Phospholipases are enzymes that possess the capacity to split ester bonds within phospholipids. The resultant effect of the hydrolysis reaction leads to the formation of several lipid products that interfere with cellular signaling (Balboa and Balsinde, 2021). The major categories of phospholipase are phospholipases A (PLA), phospholipases B (PLB), phospholipases C (PLC), and phospholipases D (PLD). PLA and PLB both have a specific potential of hydrolytic cleavage of phospholipid's acyl ester bond at site number 1 or 2 (sn-1 or sn-2). Phospholipases C can act on the cleavage of glycerophosphate bonds, while PLD targets the cleaving of the polar head group. These subfamily members are specific in the display of individual enzymatic activity, physiological state, tissue dispersal, and so on.

Phospholipases A are enzymes that target acyl ester bonds at sn-1 and sn-2 for PLA₁ and PLA₂, respectively (Fig. 1). The PLA₁ subfamily can be grouped based on the site of action into phosphatidyl serine-specific phospholipase A₁ (PS-PLA₁), membrane-bound phosphatidic acid-preferring phospholipase A₁ ((mPA-PLA₁)_{a,b}), hepatic lipase (HL), endothelial lipase (EL), pancreatic lipase-related protein 2 (PLRP2), phosphatidic acid-preferring phospholipase A₁ (PA-PLA₁), human pancreatic lipase (PL), and lipoprotein lipase (LPL). The PLA₂ subfamily can be classified into 15 types of lipases (Baba et al., 2014). The most studied types are secreted phospholipase A₂ (sPLA₂), cytosolic phospholipase A₂ (cPLA₂), platelet-activating factor-acetylhydrolase (PAF-AH), lysosomal PLA₂, and cytosolic Ca²⁺-independent phospholipase A₂ (iPLA₂). The catalytic activity takes place through membrane homeostasis by recycling




FIG. 1 Schematic of phospholipases and their catalytic sites.

fatty acid moieties by the cleaving of arachidonic acid (AA). AA, which happens to be biologically active, can be a source of starting material in the production of platelet-activating factor (PAF) and eicosanoids. These lipases are Ca^{2+} -dependent and possess a His/Asp dyad at their most active site. This active site (Fig. 1) provides the enzyme (lipase) with the capacity of performing intracellular activity locally and also in distant cells (transporting to other cells via channels).

Phospholipase B is a type of phospholipase that demonstrates hydrolyzing capability on both sn-1 and sn-2. The responsive gene for this action is in the second chromosome and is identified as PLB_1 . PLB exhibits the characteristics of both phospholipase A_2 and lysophospholipase. Initially, it is synthesized as a 170 kDa proenzyme and later transformed into an active 97 kDa enzyme through papain treatment. This is present in the sperm, epidermis, and intestine (Maury et al., 2002). Earlier research has shown that the PLB gene is a potential risk gene for rheumatoid arthritis, and further research has indicated the important role of PLB_1 in acrosome exocytosis in sperm by maintaining fertility (Okada et al., 2014).

The PLC family consists of six subfamilies: $\text{PLC}\beta$, γ , δ , ϵ , ζ , and η (Gresset et al., 2012). The receptor tyrosine kinase (RTK), the G-protein coupled receptor (GPCR), has been seen to play vital roles in the activation of PLC family members in the sites of hormones and neurotransmitters (Philip et al., 2013). For each of the subfamily identified, there is more than one variant. One of the PLC genes known as PLCB_1 , when present in neurons, can permit the migration of malignant partial seizures in infancy, schizophrenia, etc. in a state of mutation (De Filippo et al., 2014). In terms of crystallographic data, PLCs possess an X and Y domain for enzyme activity. Differing from the enzyme active site, the subfamilies indicate a Ca^{2+} -dependent phospholipid-binding site, as well as Src sites, which is seen in protein-protein interaction. $\text{PLC}\beta$ participation has been seen in the separation by regulating cyclin D3 and other cellular activities which include proliferation via the protein kinase C (PKC) α -mediated pathway (Bavelloni et al., 2015).

The PLD family can be grouped into three main types: PLD_1 , PLD_2 , and mitoPLD .

MitoPLD was only recently discovered and was found to play a vital role in mitochondrial fission and fusion reactions. PLD1 and PLD2 can be seen to play important cellular roles such as cell division, cell motility, cell survival, apoptosis, and proliferation. PLD possesses a site that can bind to actin, and this helps to improve cell motility at various phases (actin polymerization, spread to substratum, cell adhesion, and contractility) (Rudge and Wakelam, 2009). It also has the potential to hydrolyze phospholipids (phosphatidylcholine) to form choline and phosphatidic acid (PA); this reaction is controlled as cell components include phospholipids. PLD1 is compartmentalized in the secretory granules, endosome, and Golgi complex, while PLD2 is localized to the plasma membrane, and finally mitoPLD is present on the surface of the mitochondria (Oliveira and Di Paolo, 2010). MitoPLD is mainly involved in the formation of PA and the inhibition of transposon mobilization during meiosis in spermatogenesis (Gao and Frohman, 2012).

2 The role of phospholipases in inflammation

Inflammation is a highly regulated physiological response to injury which is associated with oxidative stress and the bioactive formation of lipids. Those bioactive lipids, such as oxidized phospholipids, platelet-activating factor acetylhydrolase (PAF-AH, also known as lipoprotein-associated phospholipase A₂ (Lp-PLA₂)), and PAF-like substances have been identified in several disease plaques. Lp-PLA₂ was classified as a Ca²⁺-independent PLA₂, produced by a large range of non- and inflammatory cells. In addition, as Lp-PLA₂ is specific for the breakdown of oxidized fatty acid residues and PAF, PLA₂ is specific for phospholipids containing two long-chain acyl groups (Silva et al., 2011). The enzyme A₂ (PLA₂) is an important factor in some diseases that involve inflammation, such

as lung disease (Hurley and McCormick, 2008). Phospholipase A₂ (PLA₂) catalyzes the release of arachidonic acid (AA) from the cell membrane for the generation of lipid mediators of inflammation such as leukotriene and is crucial in diverse inflammatory processes.

Certain sPLA₂ regulates an aggregation of biological functions via certain receptors called sPLA₂-receptors. Those receptors are mannose-type transmembrane glycoproteins which are related to the C-type animal lectin taxonomic group. Several of the consequential receptor-mediated functions are: (1) group X sPLA₂-receptor action for AA left behind by spleen cells; (2) group IB sPLA₂-receptor interaction for cell growth and lipid mediator making; (3) group V sPLA₂-receptor interaction for antiangiogenic and proangiogenic factors by human neutrophils (Loffredo et al., 2017); (4) group I-receptor action for prostaglandin E₂ making; and (5) group IV-receptor action for cytokine liberation (Khan et al., 2016). The sPLA₂-receptor interactions are also involved in causing certain diseases including cancer, in addition to physiological functions (Friedemann et al., 2018; Sukocheva et al., 2019).

It has been reported that cells that are deficient in V sPLA₂ have impaired eicosanoid synthesis. The remarkable function of these enzymes that likely contribute to inflammatory disease includes the stimulation of chemokines and cytokines, which are critical to the inflammatory and immune responses and generation of bioactive eicosanoids. Lp-PLA₂, a Ca²⁺-dependent, is a special member of the PLA₂ superfamily that provides materials for the production of different families of compounds which play aggregate roles in inflammation. The inflammatory role of Lp-PLA₂s has been demonstrated in multiple inflammatory disease conditions including cancer, pancreatitis, sepsis, psoriasis, and rheumatoid arthritis (Boilard et al., 2010). PLA₂ contains 15 different groups and several subgroups. These enzymes are distinguished by their capability to hydrolyze ester

bonds at the *sn*-2 position of the glycerol backbone of phospholipid substrates and are allotted to groups settled on molecular weight, sequence, the necessities for Ca^{2+} , disulfide bonding percepts, and other characteristics. The acetyl group hydrolysis at the *sn*-2 location of PAF generates lyso-PAF and acetate, and the capability of Lp-PLA₂ to deactivate PAF has been involved in different types of inflammatory diseases.

The key enzyme that is concerned with inflammation is the Ca^{2+} -dependent IVA phospholipase A₂ group, which is also called cytosolic phospholipase A₂ α (cPLA₂ α). This is as a result of the enzymes' capability to initiate eicosanoids production, such as leukotriene LTB₄, LXs, and hepxilin HXA₃, serving as a neutrophil chemoattractant, and playing a key role in the inflammatory process (Hurley and McCormick, 2008) by releasing AA preferentially in response to cell activation (Fig. 2). There are several ways by which PLA₂ participates in the inflammatory reaction. When bioactive lipids have been hydrolyzed by Lp-PLA₂, and their biological activity is reduced, the lysophospholipids become the most generated metabolites (Fig. 3). These lipids are implicated in atherosclerotic

processes and show a very harmful role of Lp-PLA₂, causing an inflammatory reaction against oxidized lipoproteins. These compounds, which are released by phospholipases A₂ during cell vivification, apoptosis, or injury, are known to distort the diversity of cell types and the function of neutrophils, and can also be generated by phospholipase A₁ and by the action of lecithin-cholesterol acyltransferase (LCAT) or endothelial lipase. There are different types of lysophospholipids, but lysophosphatidylcholine remains the main product of Lp-PLA₂ action; these metabolic action of Lp-PLA₂ happens in physiological states (Schmitz and Ruebsaamen, 2010; Silva et al., 2011).

In inflammation, AA is the most important fatty acid released by PLA₂ from phospholipids. This reaction districts the availability of AA which, in turn, is the rate-limiting precursor for the generation of prostaglandins. AA is also the precursor of leukotrienes that are formed through the lipoxygenase pathway. The bulk of lysophospholipids in some situations amounts to the generation of platelet-activating factor (PAF), which is another influential mediator of inflammation. The essential enzyme for this reaction is platelet-activating factor-acetylhydrolase (PAF-AH) (Khan and Hariprasad, 2020). Due to this property, cytosolic phospholipase A₂ α has gained pharmaceutical interest, and is used in the development of antiinflammatory drugs (Balboa and Balsinde, 2021). Due to the complexity of the lipid metabolic pathway, which is often redundant and highly interconnected, as well as the coexistence of several enzymes with phospholipase A₂ activity in the cells with overlapping activation properties, targeting and inhibiting the phospholipase A₂ reaction has proved problematic.

Another group of phospholipases A₂ that is known to take part in some of the functions of macrophages exposed to interleukin 4 (IL-4) is the group V secreted. This group modifies the cells to an antiinflammatory phenotype. This is




FIG. 2 Eicosanoid synthesis pathways occurring within a mammalian cell.




FIG. 3 The role of Lp-PLA₂ in the generation of lysophospholipids.

in accordance with the work of [Koganawasa et al. \(2021\)](#), that the mass spectrometry analysis of phospholipase A₂ substrates and products using macrophages deficient, polarized to either pro-inflammatory (bacterial lipopolysaccharide plus interferon-) phenotypes or antiinflammatory (IL-4-treated). Exclusive changes among the different vivification regimes that function critically for inflammation have been identified that may depend on the group V enzyme. This also suggests the subsistence of novel lipid pathways. The interactions between the secreted phospholipase A₂ and cPLA₂α of the monocytes in terms of lipid droplet biogenesis and eicosanoid response contribute to the initiation of the inflammatory response.

Oxidative stress and inflammation are therefore hallmarks of several diseases and are known to contribute to the initiation, progression, and herniation of lipid-rich vascular lesions ([Silva et al., 2011](#)). Lipoprotein-associated phospholipase A₂ is a special associate of the phospholipase A₂ superfamily, which is distinguished by its capacity to specifically

hydrolyze truncated and/or oxidized fatty acyl groups, platelet-activating factor, and glycerophospholipids at the *sn*-2 station of the glycerol backbone. Lipoprotein-associated phospholipase A₂ in humans moves around in an active state with high- and low-density lipoproteins as a complex. Reports from clinical studies show that plasma Lp-PLA₂ mass and activity are firmly linked with vascular risk and atherogenic lipids. The hypotheses that restriction of the activity of Lp-PLA₂ could provide a significant therapeutic strategy and that its mass level and/or activity could be utilized as biomarkers of cardiovascular disease are based on these findings ([Rosenson and Stafforini, 2012](#)).

Several genetic studies have shown that the diminution of Lp-PLA₂ utility is a risk factor for vascular conditions and inflammation. Animal model studies have also revealed that the overexpression of Lp-PLA₂ demonstrates antiatherogenic and antiinflammatory properties. This is because the production of pro-inflammatory prostaglandins and leukotrienes are been inhibited by the secretory

phospholipase A₂ (PLA₂) inhibitors (Rosenson, 2010). The balance between pro- and anti-inflammatory properties has been regulated by a variety of physiological functions, which are most often redundant mechanisms and diverse stimuli, such as transcriptional activators, receptor ligands, and environmental cues. At the transcriptional level, IFN- γ (the agent of M1 pro-inflammatory phenotypes) decreases the expression of Lp-PLA₂. M-CSF, on the other hand, which is an inducer of an M2-like, anti-inflammatory phenotype, increases the monocyte Lp-PLA₂ expression at a greater level when analogized with the M1-inducer GM-CSF (Rosenson and Stafforini, 2012). Blocking the onset of inflammation offers a therapeutic effect in different settings, but improper eclosure of it can cause disastrous short- and/or long-term effects. This is evident in the altered expression of multiple inflammatory gene products, which is associated with the development of cardiovascular disease (CVD). As such, the role of phospholipases should be assessed carefully in individual cases (Libby et al., 2002). Multiple inflammatory cells that are involved in certain disease conditions such as atherogenesis, which secretes Lp-PLA₂, include macrophages, monocytes, reactive mast cells derived from bone marrow, reactive platelets, and neutrophils, of which macrophages/monocytes are the main protagonists in the onset and advancement of such diseases. They have also been declared as novel latent therapeutic reference points for the prevention and treatment of those diseases.

3 The mechanism of action of Lp-PLA₂ on inflammation

The Lp-PLA₂-mediated decrease in the bioactivity of phospholipid substrates, such as PAF and OxPL, is the mechanism accounting for its involvement in inflammation. However, an issue that has eluded clarification despite considerable effort over the years is whether there

are generation of products in the in vivo action of Lp-PLA₂ on endogenous substrates (i.e., lyso-phosphatidylcholine (lyso-PC) plus short and/or oxidized fatty acids) which increase inflammatory reactions in the vascular wall. Specifically, it has not been ascertained if Lp-PLA₂ is detrimental or beneficial, or if the substrates are less, more, or evenly atherogenic than the spin-offs (Rosenson and Stafforini, 2012). Studies have shown that in vitro approaches have been used to distinguish the biological attributes of pertinent products and substrates of the reaction. Both anti- and pro-inflammatory activities have been accredited to glycerophospholipids shielding fragmented and/or oxidized *sn*-2 fatty acyl groups. Similarly, lyso-PC and short and/or oxidized fatty acids have been reported to elicit both detrimental and beneficial effects. For example, low (nanomolar) engrossment of lyso-PC recruit monocytes and induce pro-inflammatory cytokine production in vitro (Olofsson et al., 2008).

Close to 70%–80% of PAF-AH (Lp-PLA₂) circulating is attached to low-density lipoprotein (LDL), and the remainder is connected to high-density lipoprotein (HDL) and several very low-density lipoproteins. The two α -helices aid the enzyme affiliated with these lipoproteins. Low-density lipoprotein has an attraction in the zone between residues 126 and 114, while high-density lipid is linked with the residues 362–369 of the two α -helices. The enzyme possesses a standard lipase α/β -serine hydrolase fold and a catalytic trio comprising Ser273, His351, and Asp296. Ser273 is situated on the N-terminus of an alpha helix and the preserved motif GX SXG standard to other serine esterases and lipases. Ser273 is a nucleophilic constituent reactive for catalysis through other two constituents—His351 and Asp296. The constituents Phe274 and Leu153 act as oxyanion holes and neutralize the negative charge of tetrahedral antepenultimate through their amide nitrogens. The catalytic trio is targeted inside a hydrophobic pocket and situated near its lipid substrate.

Platelet-activating factor (PAF) is a phospholipid-signaling building block that binds its particularized receptor, leading to a succession of proinflammatory signals; therefore, PAF is a conspicuous pro-inflammatory mediator (Khan and Hariprasad, 2020).

Low-density lipoprotein, T-lymphocytes, and macrophages can transmigrate easily to arterial intima as a result of endothelial dysfunction, which is distinguished by increased adhesion molecules expression and by larger spaces between endothelial cells. Through the atherogenic mechanisms pertaining Lp-PLA₂, an individual with obesity, dyslipidemia, insulin resistance, hypertension, and oxidative stress can exist, and thus be highly inclined to atherosclerosis. The LDL particle shows a phenotype that is more atherogenic, being dense and small; these characteristics make it more susceptible to oxidation. In this site, the reduced content of antioxidants favors the high production of free radicals, and consequently oxidative modifications of LDL. Thus, the Lp-PLA₂ will be activated by oxidized phospholipids present in OxLDL.

The enzyme minimizes modifications of OxLDL, hydrolyzing its oxidized phospholipids; this may be interpreted as an antioxidant action. However, during this process, high contents of lysophospholipids and oxidized nonesterified fat acids (OxNEFAS) are produced that promote adhesion molecules expression and attract macrophages to the arterial intima. The OxLDL, lysophospholipids, and OxNEFAS also stimulate cytokines production, for example, TNF α and IL-6, which increase the inflammatory profile in the region of the plate. The activated macrophages, through scavenger receptors and phagocyte OxLDL, gradually turn up in foam cells. The muscle cells are also attracted, and migrate to the intima, where they produce collagen, elastin, and elastases, involving and stabilizing the lipid plaque. Subsequently, the macrophages become apoptotic, as well as the muscle cells, causing the release

of lipids in the plaque. In this process, the presence of OxLDL, as well as lysophospholipids and OxNEFAS produced by Lp-PLA₂, continually stimulates the growth of the plaque; these are factors that can be decisive in terms of plaque rupture susceptibility and can culminate in a cardiovascular event.

4 Phospholipases in gene expression

In molecular biology, a gene is generally referred to as the complete nucleic acid sequence that is required for the synthesis of a functional gene product (polypeptide or RNA). Genes are functional units of inheritance as they are made of deoxyribonucleic acid (DNA) or, in the case of some viruses, ribonucleic acid (RNA). Gene expression refers to the events that transfer the information content of the gene into the making of a functional product, usually a protein (Lodish et al., 2003). All the cells regulate gene expression in response to changes in the external environment. The mechanisms of gene expression are described in transcription and translation, which follow the process of initiation, elongation, and termination. A protein that modifies the activity of transcription factors and influences the expression of their target genes is referred to as a modulator. This modulator always acts by binding directly to the transfer factors to affect the expression of a target gene in which phospholipases play a significant role.

During development and differentiation, an individual cell expresses or turns on merely a segment of its genes at any given time, while the remaining genes are repressed or turned off. This process of turning genes on and off is called gene regulation. Genes are regulated using different patterns during development, such as hemoglobin, which is only expressed in developing red blood cells, even though the globin genes are found in all types of cells. Also, gene regulation enables cells to react quickly to

changes in their environments. Regulation of a gene can take place at any point during gene expression, but most commonly happens during transcription (when the information in the DNA of a gene is passed to mRNA). Signals from the environment or other cells activate proteins referred to as transcription factors, which bind to the regulatory regions of a gene, thereby increasing or decreasing the level of transcription.

Phospholipases A₁ (PLA₁), A₂, C, and D act on membrane phospholipids to produce tiny molecules which act as mediators and play vital roles in cellular metamorphosis. As the acyl groups are been cleaved at the sn-1 position by the PLA₁, phospholipases A₂ (PLA₂) are accountable for the acyl groups cleavage at the sn-2 positions of glycerophospholipids producing lysophospholipids (phospholipids containing an acyl chain) that have detergent-like properties. PLA₂s are a large group of the superfamily (more than 50 subtypes) due to their calcium dependence and cellular localization. Out of this group of PLA₂s, the calcium-independent iPLA₂, the calcium-dependent cytosolic cPLA₂, and the secretory sPLA₂, having antithetic molecular structures, cellular determination, and producing lipid mediators with varied functions, are the most studied (Murakami et al., 2020).

5 Biomedical applications of phospholipases in gene expression

Cytosolic phospholipases A₂ (cPLA₂s) are intracellular enzymes with a molecular weight of about 85 kDa, containing 749 amino acids. The cPLA₂ family has six isoforms: cPLA₂α, -β, -γ, -δ, -ε, and -ζ. cPLA₂ subgroups possess a highly conserved C₂ domain for binding Ca²⁺ and the C-terminal domain has a catalytic active site which uses the Ser-Asp dyad for catalysis except for cPLA₂, which lacks the C-domain. Phosphorylation of cPLA₂ results in an

increased phospholipid attaching at low calcium levels which assists the translocation of enzymes in the cytoplasm to various intracellular organelles comprising the mitochondrial, nuclear, plasma, and lysosomal membranes.

All the brain cells seem to contain cPLA₂α (comprising astrocytes, microglia, and neurons), which is the most studied subtype of cPLA₂. cPLA₂α has been found to stimulate neurons together with excitatory glutamate receptors that could give rise to fast activation of the Ras/Raf/MEK/ERK pathway and, subsequently, phosphorylation of cPLA₂. Toll-like receptor galvanization with lipopolysaccharide (LPS) in the microglial cells could lead to ERK1/2-dependent cPLA₂ phosphorylation induction and upregulation of the inflammatory pathway involving NFκB. Upregulation of NFκB was found to be associated with inflammatory proteins after treating microglial cells with LPS. Together, these findings show the part played by protein kinases in the cPLA₂ phosphorylation causing glial inflammation and neuronal excitation (Sun et al., 2021).

Research has revealed the part that PLA₂ played in the fast emission of polyunsaturated fatty acids (PUFAs) in the brain as a result of diverse types of injuries to the brain. Elevations in oxidative stress, glial cell activation, and neuronal excitation using an animal model have been observed, and these are features that contribute to the galvanization of cPLA₂ in cerebral ischemia. Under ischemic conditions, PLA₂-evoked emission of PUFAs is usually worsened by a shortage of oxygen and a decline in the adenosine triphosphate that is needed for the fatty acid transformation to its acyl-CoA. Accordingly, agitation of the deacylation-acylation cycle facilitated by acyltransferases and phospholipases A₂ is considered very significant for changes in cellular PUFAs and phospholipids during cerebral ischemia. An increase in PUFAs in the brain as a result of a stroke can also be seen in plasma, making the investigation of PUFAs in plasma an effective biomarker for

examining the level of brain distortion in patients with stroke.

Alzheimer's disease (AD) is a neurodegenerative disease that is noticeable when amyloid plaques and neurofibrillary tangles are deposited in the brain. The elevating concern on PLA₂ is as a result of a connection to its outputs to synaptic engagement in learning. Recent studies have revealed increased levels of cPLA₂ in the brain, brought about by changes in lipid species such as an increase in lysophospholipids in the hippocampus, more aggressive A β accumulation, reactive gliosis, and cognitive deficits.

Prostaglandins (PGs) are produced from arachidonic acid (AA) by phospholipase A₂s (PLA₂s) and subsequently by cyclooxygenases. Considering progressive events in reproduction from female ovulation to parturition, PGs are crucial. Cytosolic PLA₂s (cPLA₂s) regulated by Ca²⁺-dependent translocation and phosphorylation usually have a preference for AA in membrane phospholipids, and play a significant role in agonist-induced AA release. The cPLA₂ α -derived AA is essential for the PG synthesis that is required for on-time implantation.

Cancer is caused by spatially improper and uncontrolled cell proliferation in tissues. Cancer risks are associated with mutations in DNA, perhaps via environmentally influenced and transmissible biomarkers on the DNA. New findings have revealed that the organization of biochemical pathways can be delineated in the status of networks comprising of hubs and nodes which are similar to other haphazardly assembled, firm, self-referent organizational structures, and that many oncogenes and tumor suppressor genes react on a number of biochemical pathways. Some classes of lipid mediators are obtained initially through the action of phospholipase A₂ (PLA₂) enzymes on phospholipids, thereby releasing fatty acids and lysophospholipids with biological applications relevant to cancer progression. Each one can be metabolized further—the fatty acids by cyclooxygenase (COX), lipoxygenase (LOX), or cytochrome

P450 (CYP) enzymes, or by nonenzymatic oxidation, and the lysophospholipids by lysophospholipases, lysophospholipid acyl-CoA acyltransferases, and lysophospholipid: lysophospholipid transacylases.

A number of the PLA₂ enzymes also demonstrate lysophospholipase and/or transacylase activity, which reveals the relationship of these pathways and the intricacy with which lipid fluidity through them is restrained. More than 100 important and diverse paracrine and autocrine controllers of organ function and normal cell are produced via these pathways which regulate cellular differentiation, growth, apoptosis, and senescence, thus contributing to the homeostatic control of tissue proliferation and vascularization, tissue remodeling, and immune surveillance, particularly in reaction to stress. Together, these cellular utilities are revolutionized by tumor cells which allow them to proliferate locally and metastasize to distant sites. Out of the 22 human PLA₂ enzymes, only 10 have been determined in the human cancer context. Despite the current limitations, several works have led to new hopes that PLA₂ enzymes may be suitable targets for cancer therapy (Murakami et al., 2020).

6 Industrial applications of phospholipases

Phospholipases have many industrial applications including oil refining, dairy, baking, the health food industry, etc. PLC and PLD have chiefly been used for pharmaceutical, medical, and analytical purposes. The microbially produced PLD was used for the synthesis of chemicals by trans-phosphatidylation, which is exchange of the alcohol moiety attached to the phosphatidic acid residue. PLA₂ was reported to be the most suitable for the enzymatic degumming of edible oils and the synthesis of triglycerides enriched in polyunsaturated fatty acids (PUFAs). Genetically modified mammal, plant,

or microbially produced phospholipases are used for these purposes since microbial enzymes are cost-effective and environmentally friendly.

The essential omega fatty acids— γ -linolenic acid, arachidonic acid, and docosahexaenoic acid (DHA)—occur naturally but are usually at low levels when compared with other acids. There is high demand for these acids in industries, and although these materials can be produced by conventional physical and chemical separation methods, they are not always appropriate for nutritional applications. However, this problem has been successfully overcome by exploiting the specificity of enzymes. Phospholipase A₂ can be used to prepare phosphatidylcholine enriched with *n*3PUFA. For example, pig pancreas phospholipase A₂ was used to mediate trans-esterification of soy lecithin containing highly unsaturated fatty acids (at *sn*2 position) to produce lecithin with possible pharmaceutical, nutritional, and industrial applications.

The cholesterol content of a food (usually egg yolk, meat, fish, or dairy products) could be reduced by subjecting the food either to an enzymatic treatment (especially with cholesterol oxidase (EC 1.1 3.6) or a cholesterol oxidase-producing microorganism) or to biochemical treatment (breakdown of cholesterol). These two treatments could also be performed simultaneously. Biochemical, chemical, and/or physical treatment of food substances was improved by treating them with hydrolytic enzymes such as phospholipase A₁, phospholipase A₂, lysophospholipase phospholipase B, or phospholipase to obtain a cholesterol-reduced product (Ramrakhiani and Chand 2011).

Phospholipases (PLs) have been employed for the removal of mucilage and phosphorus components in crude vegetable oil. This could be achieved by the use of PLA₂ or PLB, but not with PLC or PLD. The phospholipase enzymatic treatment process is used to purify any edible oil containing phospholipids (e.g., vegetable oil

such as soybean oil, rape seed oil, and sunflower oil) using two steps: treating the oil with phospholipase (A₁, A₂, or B) to hydrolyze the phospholipids such as lecithin and other accompanying hydrophilic components, then separating an aqueous phase containing the hydrolyzed phospholipids from the oil.

7 Phospholipase and apoptosis

Apoptosis is a form of cell death that does not involve an inflammatory response and occurs in a tightly controlled manner. There are two main pathways through which apoptosis may occur. In the first pathway, apoptosis can be induced by a death receptor such as the tumor necrosis factor receptor; in the second one, apoptosis can be induced by cytotoxic agents that cause a mitochondria-dependent cascade of events (Thornberry and Lazebnik, 1998). In death receptor-mediated apoptosis, a death-inducing signaling complex is formed by the death receptors, adapter proteins, and caspases (cysteine-specific proteases) such as caspase-8 and caspase-10 (Chen and Wang, 2002). In mitochondria-dependent apoptosis, major alterations in mitochondrial membrane function occur. While a proper activation of the apoptotic system is important, so is the recognition and removal of apoptotic cells. Loss of normal phospholipid asymmetry in apoptosis provides an “eat me” signal to macrophages. Meanwhile, phosphatidylserine (PS) exposure is essential for platelets to induce the hemostatic process. Unwanted PS exposure as the result of inadequate removal of apoptotic cells will result in a prothrombotic state, which is often correlated with severe inflammation-induced illness. Secretory phospholipase A₂ (sPLA₂), an essential secondary messenger in inflammation, generates the building blocks for inflammatory signaling molecules such as eicosanoids and platelet-activating factor (PAF) (Frans, 2022).

In addition, sPLA₂ will hydrolyze bacterial and viral membranes, and as such assists in host defense. Unfortunately, sPLA₂ will also effectively hydrolyze PS, exposing (apoptotic) cells.

7.1 The role of PLA in apoptosis

Six major types of PLA play specific roles in apoptosis, and these are lysosomal PLA₂, sPLA₂, cPLA₂, iPLA₂β, patatin-like phospholipase A₂ (PNPLA₂), and phosphatidylserine-specific phospholipase A₁ (PS-PLA₁), all of which have been studied extensively. Other subfamilies and types of PLA mechanisms are still under study, as some have been shown not to initiate cell death.

Apoptosis, which is mostly caused by bacteria, is found in the gastrointestinal (GI) and respiratory tracts. *Escherichia coli*-like bacteria have the capacity to initiate apoptosis on epithelial cells. This is carried out by identifying the phosphatidyl ethanolamine on the plasma membrane and further expression of the outer phosphatidyl serine. The first steps will permit an increase in the accumulation of ceramide in the mitochondria. Ceramides are produced from lipids and stored in the intermembrane space. The ceramides will normally bind to sphingosine and fatty acid, as they are produced in excess during cell apoptosis. The biochemical pathways fostering the accumulation of ceramide lead to the inhibition of ceramide breakdown or activation of acidic sphingomyelinase and activation of de novo synthesis, which is responsible for the hydrolysis of sphingomyelin to ceramide (Schatter et al., 2005). During bacterial-induced apoptosis, the level of ceramide increases due to the inhibition of ceramide acylation catalyzed by PLA₂-like transacylase from phosphatidyl ethanolamine, and phosphatidyl ethanolamine substitutes as a substrate for PLD in the formation of phosphatidic acid (PA). PA serves to appropriate a balance between mitogenic and apoptotic responses (Abul-Milh et al., 2001). Since a higher concentration of PA can be found

in the cytosol, there will be an apoptotic response balance shift, and it can also be vice versa. In the final stages involving bacterial-induced margination, apoptosis, nuclear condensation, and membrane/apoptotic blebbing are seen. In this bacterial-induced cell death, the cellular response will undergo more apoptosis than necrosis; during in vitro studies, the apoptosis reaction can end up looking like necrosis. Therefore, proper observation is needed before concluding the specific death pathway initiated.

At the occurrence of an ischemic shock or seizures, there is a temporary release of AA from the brain, which is then present in the nervous system; this is called the "Bazan effect." cPLA₂ is a simpler form of intercellular PLA₂ that is found throughout the central nervous system (CNS) (Sun et al., 2004). Prions (or excess glutamate production) are potential triggers inducing cPLA₂ activation and neural death. For example, prions can initiate neurodegenerative diseases such as Creutzfeldt-Jakob disease and spongiform encephalitis. On coming into contact with neurons, cPLA₂ becomes activated and, in turn, leads to the activation of apoptosis in neural cells. On activation of cPLA₂, it is relocated to the cellular neurites through β-III-tubulin and induces the hydrolyzation of AA to prostaglandins (Last et al., 2012). Prostaglandins aid caspase-3 activation and apoptosis. cPLA₂ has also been found to play roles in the excitotoxicity initiated by glutamate and oxidative stress induced by the apoptosis of neurons. Oxidative agents elicit cPLA₂, sPLA₂, and iPLA₂ in the CNS, which induces oxidative stress-mediated cell death. iPLA₂ is strongly linked with the E and the outer mitochondrial membrane (OMM), which propels the release of cytochrome c (cyt-c) (Lei et al., 2010). N-methyl D-aspartate receptor (NMDAR) subgroup activation induces apoptosis in neurons through the further activation of NO₂ synthase and mitochondrial superoxide production (Fig. 4). Other groups including IIA sPLA₂ have a major role in the production of mitochondrial superoxide,




FIG. 4 The role of PLA₂ activation in neuronal apoptosis.

which aids the amplification of the death signal initiated by NMDAR (Chiricozzi et al., 2010).

Tumor necrosis factor alpha (TNF α) and Fas ligand (FasL) are both involved in further triggering apoptosis in cells that possess tumor necrosis factor receptor (TNFR)1/2 or Fas receptor (FasR) on their membrane; this mechanism is realized by the activation of iPLA₂. The apoptotic triggers induced by TNF α or FasL must have an activated death domain to initiate the signaling mechanism. Caspase-3 is involved in the important role of the activation and cleavage of iPLA₂ at Asp183 (Fig. 5). The trimmed iPLA₂ is the cause for the release of AA and the production of lysophosphatidylcholine, a chemo-attractant that permits phagocytic cells to remove apoptotic cells.

Caspase-3 can split at a further site, leading to separate variants of iPLA₂ (Ravichandran, 2011). Biologically active iPLA₂ exists in a homo-tetramer form, and oligomerization is a vital mechanism for regulating iPLA₂. iPLA₂ can be regulated by oxidants and lipid metabolism, leading to the inactivation of iPLA₂ by changing the oligomerization of monomers. iPLA₂ also assists in the repair of membrane phospholipids such as cardiolipin in neurons, but the repair mechanism can be altered by reactive oxygen species (ROS)-mediated peroxidation. Research has shown that iPLA₂ produces both survival and apoptotic effects in cells of the rat adrenal medulla. Also, when the ER of β -cells is exposed to stress, it leads to the




FIG. 5 The roles of PLA₂ in TNF α and Fas-induced apoptosis (Cummins et al., 2000).

reduction of ER Ca⁺⁺ stores and further activation of caspase-12. The activated caspase-12 induces caspase-3 and releases cyt-c and AA from mitochondria. The cells that contain fully developed ER indicate higher vulnerability to ER stress, and iPLA₂ was found to be involved in β cell-like cells but did not affect the neuron cells. In β cell-like cells, ceramide expression holds iPLA₂ in the “ON” or “ACTIVE” state, instead of deactivating it in the presence of ROS (Lei et al., 2010). iPLA₂ assists in the production of ceramide through acidic sphingomyelinase, but on the removal of the C-terminal region from iPLA₂VIA, it turns violent toward the cellular membrane.

The determining factor deciding the path that a dying cell will take—either apoptosis or necrosis—relies on lysosomal phospholipase A₂ (LPLA₂) activation and lysosomal permeabilization (LP). LP plays a major role in hastening the process of apoptosis induction. This is triggered by sphingosine or by the inhibition of sphingosine kinase 1, which ultimately leads to lysosomal damage. At the stage of lysosomal

damage, sPLA₂ plays a vital role in eliciting the cell osmosis-sensitive by the production of AA. LP is involved in the release of cathepsin D and the activation of caspases. This can also trigger caspase-independent cell death, where the loss of ability to bind molecules results in anoikis. LP and apoptotic traits are proportionally related (Aits and Jaattela, 2013). The sPLA₂ family permits the induction of membrane permeabilization, which in turn allows apoptotic cells to undertake phagocytosis. Normal healthy cells can become resistant to hydrolysis by the actions of sPLA₂. This then serves as an early detection that pulls macrophages toward apoptotic cells. On the other hand, PS-PLA₁ activation at the late stages of apoptosis leads to the upregulated expression of phosphatidylserine, which activates the signal “eat me” to phagocytes (Ravichandran, 2011). Extracellular matrix (ECM) interactions in normal cells can lead to several different cell fates, which are formed by integrin. The integrin’s focal adhesion kinase (FAK) signal complex has been identified as a factor in regulating anchorage-dependent cell

survival. On the inhibition or downregulation or the absence of ECM, apoptosis occurs when cells enter through anoikis via the p53-dependent pathway, which is normally activated by PKC λ and cPLA₂ (Ilić et al., 1998). Senescence occurs in cells over time; sPLA₂ is involved in senescence on the activation of the DNA-p53-dependent pathway, which is induced by the accumulation of ROS (Kim et al., 2009).

7.2 The role of PLC in apoptosis

The active PLCs that play several roles in apoptosis are phosphatidylcholine-specific phospholipase (PC-PLC), PLC γ 1, PLC γ 2, PLC δ 1, PLC δ 3, and PLC β 3. The ER releases Ca⁺⁺ from the mitochondria, which activates the apoptotic pathways and in turn induces the release of the mitochondrial pro-apoptotic factors. The ER Ca⁺⁺ depletion requires the activation of PLC and also a cytosolic Ca⁺⁺ increase (Marchi et al., 2012). During tissue remodeling, homeostasis, and cytotoxic T-cell killing, Fas/Apo-1 and TNFR1 induce apoptosis. At the point of TNFR1/Apo-1 interlinking, PC-PLC is activated and hydrolyzes phosphatidylcholine into choline and diacylglycerol. The activation of acidic sphingomyelinase requires DAG, which in turn hydrolyzes membrane sphingomyelin. In addition, it will lead to the production of ceramide through de novo synthesis. The accumulation of ceramide leads to the activation of mitogen-activated protein kinase (MAPK) and the C-Jun N-terminal kinase (JNK), which leads to the production of AA by the activation of PLA₂. Other downstream molecular signals such as PLA₂ are involved in the activation of protein phosphatase 2A and the downregulation of c-myc. The downregulation of c-myc leads to cell death by apoptosis. The apoptosis that is induced by TNF α is caused by PC-PLC (studies carried out on acute myelogenous leukemia were quantified (Plo et al., 2000)). This pathway is activated by cytotoxic T-cells to trigger apoptosis as a humoral response. At the end of apoptosis, macrophages

will consume the apoptotic materials. At the initial stages of phagocytosis, RTK-like MerTK and phosphatidyl serine identify the apoptotic bodies, and phosphoinositide phospholipase C (PI-PLC) is phosphorylated by tyrosine in the macrophage. The activated PI-PLC further hydrolyzes phosphatidyl inositol 4,5 phosphate into inositol 1,4,5-trisphosphate (IP3) and DAG. The interactions between diacylglycerol and Ca⁺² leads to the activation of PLC γ 2 and further linked with MerTK. The combination of PLC γ 2 with MerTK is an important phase of phagocytosis (Todd et al., 2004). When this combination does not occur, apoptotic bodies inflict an internal injury around the surrounding cells and this can induce autoimmunity. The FAK signaling complex contains PLC γ 1 and its absence results in anoikis (i.e., the cells begin to lose their ECM or adhesion molecules from surrounding or support cells) (Chattopadhyay and Carpenter, 2002). Severe apoptosis and dysfunctional vascularization of the placenta found in the developmental stages of the embryo are induced by the loss of PLC δ 1 and PLC δ 3 (Nakamura et al., 2005). PLC δ 1- and PLC δ 3-deficient embryos induce apoptosis in the cardiomyocytes of the growing fetus, and this leads to an increased heart weight/tibial length ratio (Nakamura et al., 2014).

7.3 The role of PLD in apoptosis

The family of PLD is divided into three types: PLD₁, PLD₂, and mitoPLD. PLD has the capacity to split phosphatidylcholine to PA. Phosphatidyl ethanolamine is a substrate of PLD and plays a vital role in altering the balance between the mitogenic and apoptotic response via the PA level. PC becomes hydrolyzed by PLD into secondary messengers known as PA and choline. On the application of shear stress to cells, the following observations were made: (1) PLD₁ activation; (2) stimulated mammalian target of rapamycin (mTOR) signaling; (3) hypertrophy; and (4) apoptosis. When the shear

stress on the plasma membrane is increased it leads to hypertrophy; cells in hypertrophy also indicate increased c-src phosphorylation and PLD₁ activation, which finally leads to apoptosis. Such apoptosis is found in renal and endothelial cells, which interact directly and regularly with shear force released by fluid motion (Huang et al., 2012). Mitochondrial phospholipase D (MitoPLD) was discovered to be located near the mitochondrial surface. It releases phosphatidic acid (PA) during meiosis of spermatocytes. Mice that are deficient in MitoPLD show a meiotic arrest of apoptosis. MitoPLD plays an important role in apoptosis and neurodegenerative diseases. The increased expression of MitoPLD at the juxtaposition of mitochondria during fusion and RNAi (RNA specific to spermatocytes) leads to mitochondria fragmentation. The apoptosis that occurs in the mitochondria of cells shows as fission rather than fusion. Mitochondrial fission has been implicated in the apoptosis upstream of cyt-c. Dynamin-related protein1 is a vital factor in mitochondrial fission and apoptosis. This type of apoptosis takes place usually during developmental stages. MitoPLD also plays a major role in the termination of mitochondrial fusion, through the activation of Lipin1b-like molecules, which boosts mitochondrial fission by converting PA into DAG.

8 Conclusion

This chapter has highlighted the various classes and subclasses of phospholipases with hydrolytic, lysophospholipase, and transacylase activity which are essential for the modulation and control of diverse cellular processes including signal transduction and inflammation, gene expression, apoptosis, and lipid fluidity. This has served to reveal the relationship of these intricate pathways and the complexity with which they are regulated. These extant multifaceted roles and mechanisms make phospholipases an

important group of enzymatic biomolecules that warrant exploitation in the biotechnological and biomedical realm. Furthermore, the fact that biotechnology provides an opportunity for microbes/cells to be specifically engineered and directed for the production of these enzymes supports their position as an important group of biomolecules with future potential and multiple applications spanning the biomedical, pharmaceutical, agriculture, and food industries.

Acknowledgment

The authors thank the management of Bingham University, Nigeria and Nuhu Bamali Polytechnic, Nigeria for providing them with a supportive environment in which to write this chapter.

References

- Abul-Milh, M., Wu, Y., Lau, B., Lingwood, C.A., Foster, D.B., 2001. Induction of epithelial cell death including apoptosis by enteropathogenic *Escherichia coli* expressing bundle-forming pili. *Infect. Immun.* 69 (12), 7356–7364.
- Aits, S., Jaattela, M., 2013. Lysosomal cell death at a glance. *J. Cell Sci.* 126, 1905–1912.
- Baba, T., Kashiwagi, Y., Arimistsu, N., Kogure, T., Edo, A., Maruyama, T., 2014. Phosphatidic acid (PA)-preferring phospholipase A1 regulates mitochondrial dynamics. *J. Biol. Chem.* 11, 497–511.
- Balboa, M.A., Balsinde, J., 2021. Phospholipases: from structure to biological function. *Biomolecules* 11, 428. <https://doi.org/10.3390/biom11030428>.
- Bavelloni, A., Dmitrienko, G.I., Goodfellow, V.J., Ghavami, A., Piazzini, M., Blalock, W., 2015. PLCβ1a and PLCβ1b selective regulation and cyclin D3 modulation reduced by kinamycin F during K562 cell differentiation. *J. Cell. Physiol.* 230, 587–594.
- Boilard, E., Lai, Y., Larabee, K., Balestrieri, B., Ghomashchi, F., Fujioka, D., Gobezie, R., Coblyn, J.S., Weinblatt, M.E., Massarotti, E.M., Thornhill, T.S., Divangahi, M., Remold, H., Lambeau, G., Gelb, M.H., Arm, J.P., Lee, D.M., 2010. A novel anti-inflammatory role for secretory phospholipase A2 in immune complex-mediated arthritis. *EMBO Mol. Med.* 2, 172–187.
- Chattopadhyay, A., Carpenter, H., 2002. PLC-γ1 is required for IGF-I protection from cell death induced by loss of extracellular matrix adhesion. *J. Cell Sci.* 115, 2233–2239.
- Chen, M., Wang, J., 2002. Initiator caspases in apoptosis signaling pathways. *Apoptosis* 7, 313–319.

- Chiricozzi, E., Fernandez-Fernandez, S., Nardicchi, V., Almeida, A., Bolanos, J.P., Goracci, G., 2010. Group IIA secretory phospholipase A₂ (GIIA) mediates apoptotic death during NMDA receptor activation in rat primary cortical neurons. *J. Neurochem.* 112, 1574–1583.
- Cummings, B.S., Mchowat, J., Schnellmann, R.G., 2000. Phospholipase A2S in cell injury and death. *J. Pharm. Exp. Ther.* 294, 793–799.
- De Filippo, M.R., Rizzo, F., Marchese, G., Giurato, G., Nassa, G., Ravo, M., 2014. Lack of pathogenic mutations in six patients with MMPSI. *Epilepsy Res.* 108, 340–344.
- Frans, A.K., 2022. Hyperinflammation, apoptosis, and organ damage. *Exp. Biol. Med.* 13, 1112–1123.
- Friedemann, M., Nacke, B., Hagelgans, A., et al., 2018. Diverse effects of phospholipase A2 receptor expression on LNCaP and PC-3 prostate cancer cell growth in vitro and in vivo. *Oncotarget* 9 (89), 35983–35996.
- Gao, Q., Frohman, M.A., 2012. Roles for the lipid-signaling enzyme MitoPLD in mitochondrial dynamics, piRNA biogenesis, and spermatogenesis. *BMB Rep.* 45, 7–13.
- Gresset, A., Sondek, J., Harden, T.K., 2012. The phospholipase C isozymes and their regulation. *Subcell. Biochem.* 58, 61–94.
- Huang, C., Bruggeman, L.A., Hydo, L.M., Miller, R.T., 2012. Shear stress induces cell apoptosis via a c-Src-phospholipase D-mTOR signaling pathway in cultured podocytes. *Exp. Cell Res.* 10, 1075–1085.
- Hurley, B.P., McCormick, B.A., 2008. Multiple roles of phospholipase A₂ during lung infection and inflammation. *Infect. Immun.* 76 (6), 2259–2272. <https://doi.org/10.1128/IAI.00059-08>.
- Ilić, D., Almeida, E.A., Schlaepfer, D.D., Dazin, P., Aizawa, S., Damsky, C.H., 1998. Extracellular matrix survival signals transduction of local adhesion kinase suppress p53-mediated apoptosis. *J. Cell Biol.* 2, 547–560.
- Khan, M.I., Hariprasad, G., 2020. Human secretory phospholipase A2 mutations and their clinical implications. *J. Inflamm. Res.* 13, 551–561.
- Khan, M.I., Gupta, A.K., Kumar, D.R., Kumar, M., Ethayathulla, A.S., Hariprasad, G., 2016. Molecular modeling of Gly80 and Ser80 variants of human group IID phospholipase A2 and their receptor complexes: potential basis for weight loss in chronic obstructive pulmonary disease. *J. Mol. Model.* 22 (9), 232.35.
- Kim, H.J., Kim, K.S., Kim, S.H., Baek, S.H., Kim, H.Y., Lee, C., Kim, J.R., 2009. Induction of cellular senescence by secretory phospholipase A2 in human dermal fibroblasts through a ROS-mediated p53 pathway. *J. Gerontol. A Biol. Sci. Med. Sci.* 3, 351–362.
- Koganesawa, M., Yamaguchi, M., Samuchiwal, S.K., Balestrieri, B., 2021. Lipid profile of activated macrophages and contribution of group V phospholipase A2. *Biomolecules* 11, 25.
- Last, V., Williams, A., Werling, D., 2012. Inhibition of cytosolic phospholipase A2 prevents prion peptide-induced neuronal damage and co-localization with beta III tubulin. *BMC Neurosci.* 13, 106.
- Lei, X., Barbour, S.E., Ramanadham, S., 2010. Group VIA Ca⁺-independent phospholipase A 2β(iPLA2β) and its role in β-cell programmed cell death. *Biochimie* 6, 627–637.
- Libby, P., Ridker, P.M., Maseri, A., 2002. Inflammation and atherosclerosis. *Circulation* 105, 1135–1143.
- Lodish, H., Berk, A., Matsudaira, P., Kaiser, A.C., Krieger, M., Scott, P.M., Zipursky, L., Darnell, J., 2003. *Molecular Cell Biology*, fifth ed., pp. 84–302.
- Loffredo, S., Borriello, F., Iannone, R., et al., 2017. Group V secreted phospholipase A2 induces the release of proangiogenic and antiangiogenic factors by human neutrophils. *Front. Immunol.* 8, 443.
- Marchi, S., Marinello, M., Bononi, A., Bonora, M., Giorgi, C., Rimessi, A., Pinton, P., 2012. Selective modulation of subtype III IP3R by Akt regulates ER Ca⁺⁺ release and apoptosis. *Cell Death Dis.* 3, 304.
- Maury, E., Prévost, M.C., Nauze, M., Redoulès, D., Tarroux, R., Charvéron, M., 2002. Human epidermis is a novel site of phospholipase B expression. *Biochem. Biophys. Res. Commun.* 2, 362–369.
- Murakami, M., Sato, H., Taketomi, Y., 2020. Updating phospholipase A2 biology. *Biomolecules* 10, 1457.
- Nakamura, Y., Hamada, Y., Fujiwara, T., Enomoto, H., Hiroe, T., Tanaka, S., 2005. Phospholipase C-δ1 and -δ3 are essential in the trophoblast for placental development. *Mol. Cell. Biol.* 10, 979–988.
- Nakamura, Y., Kanemaru, K., Kojima, R., Hashimoto, Y., Marunouchi, T., Oka, N., 2014. Simultaneous loss of phospholipase C-δ1 and phospholipase C-δ3 causes cardiomyocyte apoptosis and cardiomyopathy. *Cell Death Dis.* 5, 1215.
- Okada, Y., Diogo, D., Greenberg, J.D., Mouassess, F., Achkar, W.A., Fulton, R.S., 2014. Integration of sequence data from a consanguineous family with genetic data from an outbred population identifies PLB1 as a candidate rheumatoid arthritis risk gene. *PLoS One* 9, 87645.
- Oliveira, T.G., Di Paolo, G., 2010. Phospholipase D in brain function and Alzheimer's disease. *Biochim. Biophys. Acta* 8, 799–805.
- Olofsson, K.E., Andersson, L., Nilsson, J., Bjorkbacka, H., 2008. Nanomolar concentrations of lysophosphatidylcholine recruit monocytes and induce pro-inflammatory cytokine production in macrophages. *Biochem. Biophys. Res. Commun.* 370, 348–352.
- Philip, F., Sahu, S., Caso, G., Scarlata, S., 2013. Role of phospholipase C-β in RNA interference. *Adv. Biol. Requil.* 3, 319–330.
- Plo, I., Lautier, D., Levade, T., Sekouri, H., Jaffrézou, J.P., Laurent, G., Bettaieb, A., 2000. Phosphatidylcholine-

- specific phospholipase C and phospholipase D are respectively implicated in mitogen-activated protein kinase and nuclear factor κ B activation in tumour-necrosis-factor treated immature acute-myeloid-leukaemia cells. *Biochem. J.* 351, 459–467.
- Ramrakhiani, L., Chand, S., 2011. Recent progress on phospholipases: different sources, assay methods, industrial potential and pathogenicity. *Appl. Biochem. Biotechnol.* 164 (7), 991–1022.
- Ravichandran, K.S., 2011. Beginnings of a good apoptotic meal: the find-me and eat-me signalling pathways. *Immunity* 4, 445–455.
- Rosenson, R.S., 2010. Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes. *Curr. Opin. Lipidol.* 21, 473–480.
- Rosenson, R.S., Stafforini, D.M., 2012. Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2. *J. Lipid Res.* 53, 1767–1782.
- Rudge, S.A., Wakelam, M.J.O., 2009. Inter-regulatory dynamics of phospholipase D and the actin cytoskeleton. *Biochim. Biophys. Acta* 9, 856–861.
- Schatter, B., Jin, S., Loffelholz, K., Klein, J., 2005. Cross-talk between phosphatidic acid and ceramide during ethanol-induced apoptosis in astrocytes. *BMC Pharmacol.* 5, 3.
- Schmitz, G., Ruebsaamen, K., 2010. Metabolism and atherogenic disease association of lysophosphatidylcholine. *Atherosclerosis* 208 (1), 10–18. <https://doi.org/10.1016/j.atherosclerosis.2009.05.029>.
- Silva, I.T., Mello, A.P., Damasceno, N.R., 2011. Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A₂ (Lp-PLA₂): a review. *Lipids Health Dis.* 10, 170. <https://doi.org/10.1186/1476-511X-10-170>.
- Sukocheva, O., Menschikowski, M., Hagelgans, A., et al., 2019. Current insights into functions of phospholipase A2 receptor in normal and cancer cells: more questions than answers. Paper presented at Seminars in cancer biology.
- Sun, G.Y., Xu, J., Jensen, M.D., Simonyi, A., 2004. Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases. *J. Lipid Res.* 2, 205–213.
- Sun, G.Y., Geng, X., Teng, T., Yang, B., Appenteng, M.K., Greenlief, C.M., Lee, J.C., 2021. Dynamic role of phospholipases A2 in health and diseases in the central nervous system. *Cell* 10, 2963.
- Thornberry, N.A., Lazebnik, Y., 1998. Caspases: enemies within. *Science* 281, 1312–1316.
- Todt, J.C., Hu, B., Curtis, J.L., 2004. The receptor tyrosine kinase MerTK activates phospholipase C γ 2 during recognition of apoptotic thymocytes by murine macrophages. *J. Leukoc. Biol.* 4, 705–713.